Viz.ai launched the Viz Pulmonary Suite on May 14, 2026, an integrated AI platform designed to streamline acute and chronic pulmonary care workflows within healthcare organizations. The suite integrates with electronic health records (EHRs) to centralize patient data and features clinical guideline support to assist physicians in determining appropriate treatment steps. According to Viz.ai Chief Medical Officer Tim Showalter, M.D., the platform provides chart summarization to ensure clinicians access accurate information during patient consultations.

The solution specifically addresses conditions such as chronic obstructive pulmonary disease (COPD), lung nodules, and pulmonary embolisms. The tool includes a dedicated feature for detecting pulmonary embolisms directly on radiology scans, which Showalter noted has already contributed to decreased hospital stays and improved survival rates for affected patients. By combining these diagnostic capabilities with EHR integration, the system aims to minimize missed diagnoses and prevent treatment delays.

This release follows the March 2026 introduction of Viz Agent Studio, an agentic AI platform that enables health systems to build and scale customizable care pathways using natural language. Since its 2016 founding, Viz.ai has deployed its platform across 2,000 hospitals in the U.S. CEO and co-founder Chris Mansi, M.D., stated that this reach covers approximately two-thirds of the American population.

Viz.ai launched the Viz Pulmonary Suite on May 14, 2026, an integrated AI platform designed to streamline acute and chronic pulmonary care workflows within healthcare organizations. The suite integrates with electronic health records (EHRs) to centralize patient data and features clinical guideline support to assist physicians in determining appropriate treatment steps. According to Viz.ai Chief Medical Officer Tim Showalter, M.D., the platform provides chart summarization to ensure clinicians access accurate information during patient consultations.

The solution specifically addresses conditions such as chronic obstructive pulmonary disease (COPD), lung nodules, and pulmonary embolisms. The tool includes a dedicated feature for detecting pulmonary embolisms directly on radiology scans, which Showalter noted has already contributed to decreased hospital stays and improved survival rates for affected patients. By combining these diagnostic capabilities with EHR integration, the system aims to minimize missed diagnoses and prevent treatment delays.

This release follows the March 2026 introduction of Viz Agent Studio, an agentic AI platform that enables health systems to build and scale customizable care pathways using natural language. Since its 2016 founding, Viz.ai has deployed its platform across 2,000 hospitals in the U.S. CEO and co-founder Chris Mansi, M.D., stated that this reach covers approximately two-thirds of the American population.